GS0051: Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; systems to express therapeutic proteins in vivo; biopharmaceuticals; medicines; drugs; vaccines; in vivo cell therapies; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells; gene therapy products; gene therapy preparations; gene therapy products, namely, genetically engineered cells for transplant purposes; targeted in vivo RNA technologies; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms; cell platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gene therapy;
Case File Event Statements
3/28/2024 - 9 months ago
1 - NEW APPLICATION ENTEREDType:NWAP
3/28/2024 - 9 months ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTEREDType:NWOS
4/2/2024 - 9 months ago
3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTEREDType:NWOS
10/9/2024 - 2 months ago
4 - ASSIGNED TO EXAMINERType:DOCK
10/10/2024 - 2 months ago
6 - NON-FINAL ACTION E-MAILEDType:GNRT
10/10/2024 - 2 months ago
7 - NOTIFICATION OF NON-FINAL ACTION E-MAILEDType:GNRN